Does Momenta Pharmaceuticals, Inc. (MNTA) Have More Gas After Touching 52-Week High?

May 17, 2018 - By Eugene Smith

Investors sentiment decreased to 1.45 in Q4 2017. Its down 0.28, from 1.73 in 2017Q3. It turned negative, as 19 investors sold Momenta Pharmaceuticals, Inc. shares while 36 reduced holdings. 23 funds opened positions while 57 raised stakes. 71.96 million shares or 2.47% more from 70.23 million shares in 2017Q3 were reported.
Jpmorgan Chase has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Mason Street Advisors Limited Liability Co has 19,867 shares. Aperio Gp Ltd Liability owns 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 17,067 shares. Stifel invested in 0% or 21,824 shares. Proshare Ltd Liability Company has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Tocqueville Asset Mgmt Limited Partnership holds 0.15% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) or 963,784 shares. Riverhead Cap Management Ltd Liability reported 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Palo Alto Investors Ltd reported 1.09% stake. The New York-based American Grp Inc Inc has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Sectoral Asset Mgmt invested in 500,298 shares or 0.87% of the stock. 274,737 were accumulated by Ny State Common Retirement Fund. Gsa Cap Prtnrs Ltd Liability Partnership reported 113,294 shares. 16,086 were reported by Raymond James Associate. 15,402 were reported by Brinker Capital Inc. Grisanti Capital Management Ltd reported 6,000 shares stake.

Since December 13, 2017, it had 0 buys, and 24 selling transactions for $4.67 million activity. $8,918 worth of stock was sold by Kaundinya Ganesh Venkataraman on Tuesday, May 8. Another trade for 352 shares valued at $7,726 was sold by KWON YOUNG. 3,857 shares were sold by Stoner Elizabeth, worth $77,140 on Wednesday, April 25. Leicher Bruce had sold 471 shares worth $8,516 on Tuesday, May 8. Another trade for 3,972 shares valued at $60,216 was made by Storer Scott M on Monday, February 12.

The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) hit a new 52-week high and has $23.43 target or 3.00 % above today’s $22.75 share price. The 7 months bullish chart indicates low risk for the $1.76B company. The 1-year high was reported on May, 17 by Barchart.com. If the $23.43 price target is reached, the company will be worth $52.86M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.44% or $0.1 during the last trading session, reaching $22.75. About 125,910 shares traded. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 23.66% since May 17, 2017 and is uptrending. It has outperformed by 12.11% the S&P500.

Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on August, 1. They expect $-0.36 EPS, up 28.00 % or $0.14 from last year’s $-0.5 per share. After $-0.63 actual EPS reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -42.86 % EPS growth.

More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Nasdaq.com which released: “Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018” on May 10, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” published on May 10, 2018, Nasdaq.com published: “Momenta Pharmaceuticals Announces Date of First Quarter 2018 Financial Results Conference Call and Webcast” on May 01, 2018. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Nasdaq.com and their article: “Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update” published on May 08, 2018 as well as Nasdaq.com‘s news article titled: “Momenta Pharmaceuticals Contemplates Its Future” with publication date: May 15, 2018.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company has market cap of $1.76 billion. The companyÂ’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. It currently has negative earnings. The Company’s biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: